Current Advances in the Treatment of Autoinflammatory Disorders

Autoinflammatory disorders arise from dysregulated innate immunity, most commonly involving inflammasome activation and excessive interleukin-1 (IL-1) signaling. Although rare, these conditions are increasingly recognized across age groups as genetic testing expands and phenotypic classification improves. Therapeutic strategies focus on nonspecific immunosuppression of innate immune pathways. Corticosteroids remain effective for rapid suppression of acute inflammatory activity; however, their use is limited due to long-term toxicity. Colchicine is the first-line treatment for many autoinflammatory diseases, yet colchicine-resistant patients will require biologic therapy. IL-1 blockade represents the major therapeutic breakthrough across autoinflammatory syndromes. Anakinra, canakinumab, and rilonacept rapidly control symptoms and reduce the usage of corticosteroids. These agents are effective in cryopyrin-associated periodic syndromes, tumor necrosis factor receptor–associated periodic syndrome (TRAPS), mevalonate kinase deficiency, colchicine-resistant familial Mediterranean fever, and adult-onset Still’s disease. In selected phenotypes, alternative cytokine targeting is appropriate. Tumor necrosis factor inhibitors may benefit TRAPS, whereas IL-6 blockade is effective in Still’s disease–spectrum disorders. Increasing evidence supports the use of JAK inhibitors in interferon-mediated and complex autoinflammatory conditions that are resistant to other therapeutic agents. A new generation of direct inhibitors of the Nod-like receptor pyrin domain-containing 3 (NLRP3) inflammasome is in clinical development. These small molecules aim to suppress upstream inflammasome activation. Earlier diagnosis, rapid control of inflammation, improved quality of life, and prevention of long-term organ damage remain central goals. Guided therapy, cytokine profiling, and treat-to-target strategies using biomarkers together with long-acting biologics and oral inflammasome inhibitors are likely to be the mainstay of therapy over the coming decade. The treatment landscape for autoinflammatory disorders has significantly advanced, with targeted modulation of innate immune pathways and IL-1 blockade forming the backbone of therapy. Promising inflammasome-directed therapies and precision medicine approaches are expected to enhance long-term patient outcomes.